U.S. FDA· @FDA · X·· 5 天前精选AI 评分58
AI 导读
FDA 宣布对一款治疗局部晚期或转移性 RET 融合阳性实体瘤的药物给予传统批准，适用人群为 2 岁及以上儿童患者。FDA 称这是儿童肿瘤治疗领域的进展，并链接了该药（selpercatinib）的批准信息页面。
推荐理由
FDA 对 RET 融合阳性实体瘤的儿童适应症给出传统批准，可了解该靶向药在儿科人群中的监管进展。
正文
The FDA has been making real progress when it comes to treatments for childhood cancer. Just recently the FDA granted traditional approval to a treatment for locally advanced or metastic RET fusion-positive solid tumors for pediatric patients 2+. Science delivers hope to children living with cancer. #ChildhoodCancerMonth https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-traditional-approval-selpercatinib-locally-advanced-or-metastatic-ret-fusion-positive
来源：U.S. FDA · x.com